On the evening of May 17, Haier Biotechnology (688139) announced that Qijun Investment, a shareholder holding 7.79% of the shares, plans to reduce its holdings by no more than 3,179,500 shares, that is, no more than 1% of the company's total share capital, and no more than 1,907,700 shares through block trading, that is, no more than 0.6% of the company's total share capital, and a total reduction of no more than 1.6% of the company's total share capital.
As of the disclosure date of this announcement, Qijun Investment held 24,779,900 shares of Haier Biotech, accounting for 7.79% of the company's total share capital, and was the third largest shareholder of the company, of which 24,779,900 shares were tradable with unrestricted conditions. It is worth mentioning that Qijun Investment just reduced its holdings by 850,000 shares 20 days ago, with a reduction ratio of 0.27%, and the relevant information was not shown in the previous announcement.
In terms of performance, Haier Biotech's revenue in the first quarter of 2024 was about 687 million yuan, an increase of 0.04% year-on-year; net profit attributable to shareholders of listed companies was about 138 million yuan, an increase of 0.06% year-on-year. Among them, the life science segment achieved revenue of 350 million yuan, an increase of 79% month-on-month; The medical innovation segment achieved revenue of 334 million yuan, an increase of 31% quarter-on-quarter.
Recently, Haier Biotech disclosed at the performance briefing that in the first quarter of 2024, the company's overseas business continued to expand, and overseas revenue of 186 million yuan was realized
According to public information, Haier Biotech's main business is for life science users such as pharmaceutical and biological enterprises, university and scientific research institutions, and medical and health users such as hospitals, disease control, blood banks, and grassroots public health, forming two major sectors of life science and medical innovation, and providing comprehensive solutions for digital scenarios represented by smart laboratories, digital hospitals, smart public health, and smart blood.
In the secondary market, as of the close of trading on the 17th, Haier Biotech reported 39.98 yuan per share, up 3.20%, with a total market value of 12.712 billion yuan. In the past month, Haier Biotech's share price has risen by nearly 50%.
Source: Reading and Entrepreneurship